Table 1 Demographic characteristics n = 88
Gender | Â |
|---|---|
 Male | n = 53 (60%) |
 Female | n = 35 (40%) |
Age (years) | Â |
 Median | 51 |
 IQR | 33–63 |
Organ transplanted | Â |
 Kidney | n = 31 (35.2%) |
 Lung | n = 20 (22.7%) |
 Liver | n = 15 (17.1%) |
 Hematopoietic stem cell transplantation | n = 10 (11.4%) |
 Heart | n = 6 (6.8%) |
 Multi-organ | n = 6 (6.8%) |
Morphology | Â |
 Non-destructive | n = 8 (9%) |
 Polymorphic | n = 10 (11.4%) |
 Monomorphic | n = 68 (77.3%) |
 Classic Hodgkin Lymphoma | n = 2 (2.3%) |
EBV tumor status | Â |
 Positive | n = 50 (56.8%) |
 Negative | n = 38 (43.2%) |
Onset PTLD | Â |
 Early (< 1 year) | n = 21 (23.9%) |
 Late (> = 1 year) | n = 67 (76.1%) |
Ann Arbor staging | Â |
 I | n = 7 (8%) |
 II | n = 12 (13.6%) |
 III | n = 12 (13.6%) |
 IV | n = 57 (64.8%) |
Extranodal involvement | Â |
 Yes | 62 (70.5%) |
 No | 26 (29.5%) |
Hypoalbuminemia | Â |
 Yes | n = 35 (40%) |
 No | n = 53 (60%) |
International Prognostic Index | Â |
 0 | n = 9 (10.2%) |
 1 | n = 13 (14.8%) |
 2 | n = 24 (27.3%) |
 3 | n = 32 (36.3%) |
 4 | n = 8 (9.1%) |
 5 | n = 2 (2.3%) |
Baseline therapy | Â |
 Rituximab | n = 58 (65.9%) |
 Chemotherapy | n = 19 (21.6%) |
 Other | n = 4 (4.5%) |
 Missing | n = 7 (8%) |
Outcome* | Â |
 Alive | n = 51 (58%) |
 Deceased | n = 36 (40.9%) |
 Lost to follow-up | n = 1 (1.1%) |
Cause of Death | Â |
 PTLD | n = 19 (53%) |
 Therapy-related complication | n = 6 (17%) |
 Other/Unknown | n = 11 (30%) |
Metabolic tumor volume (mL) | Â |
 Median | 272 |
 IQR | 42–566 |
Total lesion glycolysis (grams) | Â |
 Median | 1825 |
 IQR | 232–5610 |